Abcuro, Inc. raised $200 million in a Series C financing led by New Enterprise Associates to advance its first-in-class medicine targeting inclusion body myositis.
PRIVATEFeb 12, 2025
Amount Raised
$200 Million
Round Type
Series C
NewtonvilleBiotechnologyHealth CareTherapeutics
Investors
Eurofarma VenturesSamsara BiocapitalMass General Brigham VenturesBain Capital Life SciencesRA Capital ManagementAbrdn Inc.BlackrockSoleus CapitalPontifaxForesite CapitalNew Leaf VenturesRedmile GroupSanofi VenturesNew Enterprise Associates
Description
Abcuro, Inc. announced the closing of a $200 million Series C financing to support the registrational Phase 2/3 MUSCLE clinical trial for ulviprubart, a novel monoclonal antibody. The funding will also facilitate the commercial launch preparation assuming positive trial results.
Who to call at Abcuro, and when
A new round usually means Abcuro is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Abcuro raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Abcuro, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Abcuro
Location
55 Chapel Street Suite 200
Newtonville, Massachusetts, United States
About
Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008, a first-in-class anti-KLRG1 antibody designed to deplete cytotoxic T cells that attack healthy muscle tissue in patients with inclusion body myositis (IBM), into clinical studies. IBM is a progressive and debilitating inflammatory skeletal muscle condition with no available pharmaceutical therapies. Abcuro has received FDA orphan drug designation for ABC008 in IBM. The company is also advancing ABC015, an anti-KLRG1 blocking antibody capable of reactivating inhibited cytotoxic T and NK cells in the tumor microenvironment.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Abcuro raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
NewtonvilleBiotechnologyHealth CareTherapeutics